Press "Enter" to skip to content

Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma – Nasdaq

admin 0

Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma  Nasdaq

MENLO PARK, Calif., April 26, 2019– Forty Seven Inc., a clinical-stage company immuno-oncology company focused on developing therapies to activate.

“lymphoma cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *